Taivex received US FDA Investigational New Drug Application (IND) Approval for T-1301 on June 17, 2021, to initiate phase I clinical trial for the treatment of advanced solid tumors.

T-1301 is a small molecular oral anti-cancer drug licensed from National Health Research Institutes in 2019. After completion of pre-clinical safety evaluation, as well as chemistry, manufacture and control of drug substance and drug products, it is anticipated to enter clinical development of T-1301 by end of 2021.